Skip to main content

Prostate Cancer: Research

Question for Department of Health and Social Care

UIN 33358, tabled on 14 July 2021

To ask the Secretary of State for Health and Social Care, with reference to the Government announcement in April 2018 of £75 million funding over five years for prostate cancer research, how much of that funding has been disbursed, broken down by project.

Answered on

22 July 2021

The Department funds research into all aspects of human health, including prostate cancer, through the National Institute for Health Research (NIHR) at the level of £1 billion per year. The following table shows the NIHR’s programme expenditure specifically prostate cancer since April 2018:

Award title

Total award budget

A randomised controlled trial of Partial prostate Ablation versus Radical Treatment (PART) in intermediate risk, unilateral clinically localised prostate cancer

£ 2,677,446

Enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359]

£ 65,625

A randomised controlled trial of TRANSrectal biopsy versus Local Anaesthetic Transperineal biopsy Evaluation (TRANSLATE) of potential clinically significant prostate cancer

£ 1,072,414

Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer [ID1443]

£ 65,625

Olaparib for previously treated, hormone-relapsed metastatic prostate cancer (ID1640)

£ 131,250

Perineal biopsy devices for diagnosis of prostate cancer in people with suspected prostate cancer

£ 175,219

A miniature tethered drop-in laparoscopic molecular imaging probe for intraoperative decision support in minimally invasive prostate cancer surgery

£ 869,105

Prostate Liquid Biopsy Test for Risk Stratification of Prostate Cancer, preparation for CE marking.

£ 205,098

Transforming management of advanced prostate cancer: Increasing clinical productivity and capacity and empowering men through digital health

£ 149,168

Further development of and evidence generation for a precision dosing tool for optimising chemotherapy dosing in advanced prostate cancer

£ 150,000

GlycoScore: Superior prostate cancer diagnosis using a simple blood test

£ 150,000

Integrating genetic testing into the prostate cancer pathway to more precisely guide care, treatment and accelerate clinical trials

£ 3,001,779

SUrvivors' Rehabilitation Evaluation after CANcer (SURECAN)

£ 2,447,636

Supported exercise TrAining for Men with prostate caNcer on Androgen deprivation therapy – STAMINA

£ 2,497,723

Endoscopically-delivered Purastat for the treatment of haemorrhagic radiation proctopathy: a randomised feasibility study

£ 225,720

Improving self and clinical management of comorbid diabetes during cancer treatments: a qualitative interview study with patients and clinicians to identify theory-based intervention targets, strategies and implementation options

£ 149,784

A multicentre randomised controlled trial (RCT) of a self-help cognitive behavioural therapy (CBT) intervention to reduce the impact of hot flush and night sweat (HFNS) symptoms in men with prostate cancer undergoing androgen deprivation therapy (ADT): MANaging symptoms during prostate CANcer treatment (MANCAN2)

£ 348,659

The Prostate Cancer Androgen Receptor Splice Variant 7 Biomarker Trial (The VARIANT trial) - A multicentre feasibility study of biomarker-guided personalised treatment in advanced prostate cancer.


Improving outcomes for men undergoing surgery for prostate cancer. A study to evaluate the feasibility of a multicentre randomised controlled trial of frozen section technology to improve oncological and functional outcomes at robotic radical prostatectomy.

£ 249,302

Multimodal treatment for patients with prostate cancer: a national study using existing electronic data.

£ 257,830



The NIHR also supports the delivery in the health and care system of prostate cancer research funded by research funding partners in the charity and public sectors. The NIHR Clinical Research Network has supported over 90 prostate cancer related studies since April 2018, totalling £20.3 million.